StocksFundsScreenerSectorsWatchlists
KZR

KZR - Kezar Life Sciences Inc Stock Price, Fair Value and News

0.92USD+0.02 (+2.22%)Delayed as of 28 Mar 2024, 10:02 am ET

Market Summary

KZR
USD0.92+0.02
Delayedas of 28 Mar 2024, 10:02 am
2.22%

KZR Stock Price

View Fullscreen

KZR RSI Chart

KZR Valuation

Market Cap

65.5M

Price/Earnings (Trailing)

-0.64

Price/Sales (Trailing)

9.36

Price/Free Cashflow

-0.79

KZR Price/Sales (Trailing)

KZR Profitability

Return on Equity

-54.31%

Return on Assets

-46.05%

Free Cashflow Yield

-127.37%

KZR Fundamentals

KZR Revenue

Revenue (TTM)

7.0M

Rev. Growth (Qtr)

-100%

KZR Earnings

Earnings (TTM)

-101.9M

Earnings Growth (Yr)

-77.44%

Earnings Growth (Qtr)

-39.64%

Breaking Down KZR Revenue

52 Week Range

0.903.37
(Low)(High)

Last 7 days

10.2%

Last 30 days

15.5%

Last 90 days

14.1%

Trailing 12 Months

-74.2%

How does KZR drawdown profile look like?

KZR Financial Health

Current Ratio

11.66

Debt/Equity

0.05

Debt/Cashflow

-8.16

KZR Investor Care

Shares Dilution (1Y)

2.82%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230007.0M
20220000
20210000

Tracking the Latest Insider Buys and Sells of Kezar Life Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 15, 2023
morningside venture investments ltd
gifted
-
-
-3,500,000
-
Jul 20, 2023
kirk christopher j.
acquired
44,055
0.9
48,950
-
Feb 06, 2023
morningside venture investments ltd
sold
-275,320
6.883
-40,000
-
Feb 03, 2023
morningside venture investments ltd
sold
-178,650
7.146
-25,000
-
Feb 02, 2023
morningside venture investments ltd
sold
-359,500
7.19
-50,000
-
Feb 01, 2023
morningside venture investments ltd
sold
-278,000
6.95
-40,000
-
Jan 31, 2023
morningside venture investments ltd
sold
-212,400
7.08
-30,000
-
Jan 30, 2023
morningside venture investments ltd
sold
-207,300
6.91
-30,000
-
Jan 25, 2023
morningside venture investments ltd
sold
-342,500
6.85
-50,000
-
Jan 24, 2023
morningside venture investments ltd
sold
-558,400
6.98
-80,000
-

1–10 of 50

Which funds bought or sold KZR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
177
177
-%
Mar 11, 2024
VANGUARD GROUP INC
added
0.75
-715,930
2,902,340
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
reduced
-36.07
-809,289
838,868
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-8,776
33,607
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
247,000
247,000
0.02%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-12,000
44,000
-%
Feb 15, 2024
Palo Alto Investors LP
sold off
-100
-780,878
-
-%
Feb 15, 2024
BARCLAYS PLC
added
678
78,000
93,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
65,780
65,780
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-1,653
6,456
-%

1–10 of 47

Are Funds Buying or Selling KZR?

Are funds buying KZR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KZR
No. of Funds

Unveiling Kezar Life Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
barclays plc
5.27%
3,827,356
SC 13G
Feb 14, 2024
avidity partners management lp
6.9%
5,025,454
SC 13G/A
Feb 14, 2024
orbimed advisors llc
2.7%
1,927,000
SC 13G/A
Feb 13, 2024
prosight management, lp
4.6%
3,365,333
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
9.9%
7,167,591
SC 13G/A
Jan 29, 2024
blackrock inc.
6.6%
4,817,266
SC 13G/A
Jan 23, 2024
state street corp
1.54%
1,116,052
SC 13G/A
Jan 22, 2024
millennium management llc
4.0%
2,927,563
SC 13G/A
Aug 17, 2023
morningside venture investments ltd
2.68%
1,947,993
SC 13D/A
Jun 21, 2023
millennium management llc
5.2%
3,780,534
SC 13G

Recent SEC filings of Kezar Life Sciences Inc

View All Filings
Date Filed Form Type Document
Mar 22, 2024
424B5
Prospectus Filed
Mar 14, 2024
S-8
Employee Benefits Plan
Mar 14, 2024
8-K
Current Report
Mar 14, 2024
10-K
Annual Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Kezar Life Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Kezar Life Sciences Inc News

Latest updates
InvestorsObserver • 22 Mar 2024 • 11:16 am
Defense World • 19 Mar 2024 • 06:55 am
InvestorPlace • 14 Mar 2024 • 07:00 am
Business Wire • 08 Mar 2024 • 09:05 pm
InvestorsObserver • 29 Feb 2024 • 08:00 am
Markets Insider • 25 Feb 2024 • 08:00 am

Kezar Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42021Q4
Revenue-100.0%-7,000----
Operating Expenses6.3%34,58932,52726,78424,52420,03414,103
  S&GA Expenses-34.5%5,7608,7895,7856,2065,1754,322
  R&D Expenses-4.6%22,64223,73820,99918,31814,8599,781
Interest Expenses0.8%399396385370349159
Net Income-39.6%-32,260-23,103-24,308-22,199-18,181-14,212
Net Income Margin-Infinity%-14.55*-----
Free Cashflow6.7%-18,981-20,341-22,976-21,157-16,226-11,347
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-11.3%22124926328430030531825221813114015215216116813590.0098.00105113115
  Current Assets-10.2%20723124426528629931124621212513314614515416112781.0089.0096.00104110
    Cash Equivalents33.9%35.0026.0028.0036.0040.0064.0010539.0063.0057.0026.0023.0021.0013.0017.0021.0015.0020.0013.0018.0024.00
  Net PPE-11.2%4.004.005.005.003.003.004.003.003.003.003.003.003.004.004.004.004.005.005.005.005.00
Liabilities1.0%34.0033.0031.0032.0030.0022.0020.0020.0021.0011.0010.0012.0011.0011.0010.0012.0011.0011.0011.0011.006.00
  Current Liabilities6.4%18.0017.0014.0014.0011.0010.008.007.008.008.006.008.006.006.005.007.006.005.005.005.003.00
  Long Term Debt-100.0%-10.0010.0010.0010.0010.0010.0010.0010.00------------
    LT Debt, Non Current0.6%10.0010.0010.0010.0010.0010.0010.0010.0010.00------------
Shareholder's Equity-13.2%18821623225227028329723219711913014114115015812378.0086.0095.00102109
  Retained Earnings-10.1%-350-318-295-271-248-230-212-196-180-166-152-139-126-115-103-94.30-84.28-74.70-65.56-56.84-49.19
  Additional Paid-In Capital0.6%538535528524520515511430378286282280267265262217163161160159158
Shares Outstanding0.1%73.0073.0073.0071.0068.0066.0064.0061.0056.0052.0052.0051.00---------
Float-------551---252---174---119--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations6.1%-18,980-20,205-21,600-20,860-15,883-16,360-13,289-13,314-11,081-9,954-13,045-8,357-9,307-9,250-10,091-8,301-7,210-8,255-7,712-6,700-5,473
  Share Based Compensation-51.5%3,2206,6344,0204,2633,8173,7873,2983,1041,8531,8781,9371,9281,2801,2711,2191,1731,0071,0901,009901449
Cashflow From Investing50.1%27,87818,57413,20316,391-8,661-24,7081,510-59,533-82,49138,48416,250-68717,3182,790-37,276-39,3301,67815,6232,142976-9,916
Cashflow From Financing37.2%59.0043.0038215450618578,32248,84899,3562,21228210,7353171,96243,99553,36880.008.001804.005.00

KZR Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Collaboration revenue$ 7,000$ 0$ 0
Operating expenses:   
Research and development85,69751,00938,935
General and administrative26,54020,15315,724
Restructuring and impairment charges6,18700
Total operating expenses118,42471,16254,659
Loss from operation(111,424)(71,162)(54,659)
Interest income11,1044,108188
Interest expense(1,550)(1,185)(159)
Net loss$ (101,870)$ (68,239)$ (54,630)
Net loss per common share, Basic$ (1.4)$ (1.01)$ (1.04)
Net loss per common share, Diluted$ (1.4)$ (1.01)$ (1.04)
Weighted-average shares used to compute net loss per common share, basic72,553,64567,368,93552,759,335
Weighted-average shares used to compute net loss per common share, diluted72,553,64567,368,93552,759,335

KZR Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 35,493$ 40,456
Marketable securities165,879236,105
Prepaid expenses and other current assets5,5789,161
Total current assets206,950285,722
Property and equipment, net3,9123,431
Operating lease right-of-use asset4,7789,741
Other assets5,595674
Total assets221,235299,568
Current liabilities:  
Accounts payable8,2512,479
Accrued liabilities6,4815,953
Operating lease liabilities, current3,0122,565
Total current liabilities17,74410,997
Operating lease liabilities, noncurrent5,8528,865
Long-term debt10,0699,834
Total liabilities33,66529,696
Stockholders' equity:  
Common stock, $0.001 par value, 250,000,000 and 125,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 72,779,077 and 68,493,429 shares issued and outstanding as of December 31, 2023 and 2022, respectively7368
Preferred stock, $0.001 par value, 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2023 and 202200
Additional paid-in capital538,390519,620
Accumulated other comprehensive loss(130)(923)
Accumulated deficit(350,763)(248,893)
Total stockholders' equity187,570269,872
Total liabilities and stockholders' equity$ 221,235$ 299,568
KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.kezarlifesciences.com
 EMPLOYEES84

Kezar Life Sciences Inc Frequently Asked Questions


What is the ticker symbol for Kezar Life Sciences Inc? What does KZR stand for in stocks?

KZR is the stock ticker symbol of Kezar Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kezar Life Sciences Inc (KZR)?

As of Wed Mar 27 2024, market cap of Kezar Life Sciences Inc is 65.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers. The fair value of Kezar Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kezar Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KZR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kezar Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether KZR is over valued or under valued. Whether Kezar Life Sciences Inc is cheap or expensive depends on the assumptions which impact Kezar Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KZR.

What is Kezar Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, KZR's PE ratio (Price to Earnings) is -0.64 and Price to Sales (PS) ratio is 9.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KZR PE ratio will change depending on the future growth rate expectations of investors.